


ILCC 2026 Top 5: The Data Shaping Lung Cancer Care

The 27th Annual International Lung Cancer Congress® brought a packed agenda of practice-informing data. OncLive® breaks down the 5 stories physicians are talking about most:



Lung Cancer Experts Debate Disease Nuances to Deliver Patient-Centered Care

A panel including Narjust Florez, MD; Lyudmila A. Bazhenova, MD; Xiuning Le, MD, PhD; Edward B. Garon, MD, MS; and Pasi A. Jänne, MD, PhD, worked through real second- and third-line treatment decisions in *EGFR*-mutant NSCLC, from *MET* IHC 3+ disease progressing on osimertinib to how (and whether) to factor in *P53* mutation subtypes.

Kandel R. Lung cancer experts debate disease nuances to deliver patient-centered care. *OncLive*. Published online July 30, 2026



Targeted Therapy Expands Into Adjuvant and Neoadjuvant Settings for Oncogene-Driven Early-Stage NSCLC

David R. Gandara, MD, reviewed how osimertinib and alectinib have become phase 3-backed adjuvant standards in resectable *EGFR*-mutant and *ALK*-positive NSCLC, with ADAURA now showing a 5-year OS benefit. He also flagged *RET* (via LIBRETTO-432) as a newly emerging adjuvant target and cautioned that neoadjuvant TKI data, while promising, aren't yet practice-changing.


OncLive Staff Targeted Therapy Expands Into Adjuvant and Neoadjuvant Settings for Oncogene-Driven Early-Stage NSCLC *OncLive*. Published online July 29, 2026



Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings

Heather A. Wakelee, MD, FASCO, presented 5-year CheckMate 816 data: neoadjuvant nivolumab plus chemotherapy improved EFS (49% vs 34%) and OS (65% vs 55%) over chemotherapy alone, though the OS benefit in stage II/III disease held only for PD-L1-positive tumors. She also walked through adjuvant and perioperative ICI trial data (IMpower010, KEYNOTE-671, CheckMate 77T, AEGEAN) and where biomarker selection still falls short.


OncLive Staff Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings *OncLive*. Published online July 28, 2026



AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer

Marina Chiara Garassino, MD, reported that AI-designed drugs are hitting phase 1 success rates of 80%-90%, roughly doubling the odds a molecule reaches market. She also detailed an autonomous AI oncology agent that hit ~87% accuracy across 20 patient cases, and explainable AI features that improved physicians' prognosis predictions, especially among nonexperts.

Kyle Doherty AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer *OncLive*. Published online July 27, 2026



ctDNA MRD Testing Helps Predict Outcomes in NSCLC

Max Diehn, MD, PhD, explained why a ctDNA MRD result isn't as simple as positive or negative: a positive result carries a >90%-95% recurrence risk, but up to two-thirds of patients who recur test falsely negative first. Tumor-informed assays remain the most sensitive option, and Medicare now reimburses testing, though NCCN guidelines haven't caught up.

Riley Kandel ctDNA MRD Testing Helps Predict Outcomes in NSCLC *OncLive*. Published online July 29, 2026